TY - JOUR
T1 - Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
AU - Ibrahim, Nasrien E.
AU - McCarthy, Cian P.
AU - Shrestha, Shreya
AU - Gaggin, Hanna K.
AU - Mukai, Renata
AU - Szymonifka, Jackie
AU - Apple, Fred S.
AU - Burnett, John C.
AU - Iyer, Seethalakshmi
AU - Januzzi, James L.
N1 - Publisher Copyright:
© 2019 American College of Cardiology Foundation
PY - 2019/3/26
Y1 - 2019/3/26
N2 - Background: With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether change in BNP concentrations is similar across all assays for its measurement. Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are unknown. Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP 1-108 , or C-type natriuretic peptide (CNP) is not well understood. Objectives: This study sought to examine the effects of sacubitril/valsartan on results from different natriuretic peptide assays. Methods: Twenty-three consecutive stable patients with heart failure and reduced ejection fraction were initiated and titrated on sacubitril/valsartan. Change in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP 1-108 , and CNP were measured over 3 visits. Results: Average time to 3 follow-up visits was 22, 46, and 84 days. ANP rapidly and substantially increased with initiation and titration of sacubitril/valsartan, more than doubling by the first follow-up visit (+105.8%). Magnitude of ANP increase was greatest in those with concentrations above the median at baseline (+188%) compared with those with lower baseline concentrations (+44%); ANP increases were sustained. Treatment with sacubitril/valsartan led to inconsistent changes in BNP, which varied across methods assessed. Concentrations of MR-proANP, NT-proBNP, and proBNP 1-108 variably declined after treatment; whereas CNP concentrations showed no consistent change. Conclusions: Initiation and titration of sacubitril/valsartan led to variable changes in concentrations of multiple natriuretic peptides. These results provide important insights into the effects of sacubitril/valsartan treatment on individual patient results, and further suggest the benefit of neprilysin inhibition may be partially mediated by increased ANP concentrations.
AB - Background: With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether change in BNP concentrations is similar across all assays for its measurement. Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are unknown. Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP 1-108 , or C-type natriuretic peptide (CNP) is not well understood. Objectives: This study sought to examine the effects of sacubitril/valsartan on results from different natriuretic peptide assays. Methods: Twenty-three consecutive stable patients with heart failure and reduced ejection fraction were initiated and titrated on sacubitril/valsartan. Change in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP 1-108 , and CNP were measured over 3 visits. Results: Average time to 3 follow-up visits was 22, 46, and 84 days. ANP rapidly and substantially increased with initiation and titration of sacubitril/valsartan, more than doubling by the first follow-up visit (+105.8%). Magnitude of ANP increase was greatest in those with concentrations above the median at baseline (+188%) compared with those with lower baseline concentrations (+44%); ANP increases were sustained. Treatment with sacubitril/valsartan led to inconsistent changes in BNP, which varied across methods assessed. Concentrations of MR-proANP, NT-proBNP, and proBNP 1-108 variably declined after treatment; whereas CNP concentrations showed no consistent change. Conclusions: Initiation and titration of sacubitril/valsartan led to variable changes in concentrations of multiple natriuretic peptides. These results provide important insights into the effects of sacubitril/valsartan treatment on individual patient results, and further suggest the benefit of neprilysin inhibition may be partially mediated by increased ANP concentrations.
KW - biomarkers
KW - heart failure
KW - natriuretic peptides
KW - neprilysin
UR - http://www.scopus.com/inward/record.url?scp=85062731100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062731100&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.12.063
DO - 10.1016/j.jacc.2018.12.063
M3 - Article
C2 - 30898202
AN - SCOPUS:85062731100
SN - 0735-1097
VL - 73
SP - 1273
EP - 1284
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 11
ER -